Bedel Financial Consulting’s Sangamo Therapeutics SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-730
| Closed | -$4K | – | 760 |
|
|
2022
Q1 | $4K | Hold |
730
| – | – | ﹤0.01% | 807 |
|
|
2021
Q4 | $5K | Hold |
730
| – | – | ﹤0.01% | 792 |
|
|
2021
Q3 | $7K | Hold |
730
| – | – | ﹤0.01% | 735 |
|
|
2021
Q2 | $9K | Hold |
730
| – | – | ﹤0.01% | 696 |
|
|
2021
Q1 | $9K | Hold |
730
| – | – | ﹤0.01% | 662 |
|
|
2020
Q4 | $11K | Buy |
730
+80
| +12% | +$1.21K | ﹤0.01% | 540 |
|
|
2020
Q3 | $6K | Hold |
650
| – | – | ﹤0.01% | 592 |
|
|
2020
Q2 | $6K | Sell |
650
-10,000
| -94% | -$92.3K | ﹤0.01% | 565 |
|
|
2020
Q1 | $68K | Buy |
10,650
+10,000
| +1,538% | +$63.9K | 0.05% | 230 |
|
|
2019
Q4 | $5K | Hold |
650
| – | – | ﹤0.01% | 593 |
|
|
2019
Q3 | $6K | Hold |
650
| – | – | ﹤0.01% | 550 |
|
|
2019
Q2 | $7K | Hold |
650
| – | – | ﹤0.01% | 532 |
|
|
2019
Q1 | $6K | Hold |
650
| – | – | ﹤0.01% | 551 |
|
|
2018
Q4 | $7K | Hold |
650
| – | – | 0.01% | 511 |
|
|
2018
Q3 | $9K | Hold |
650
| – | – | 0.01% | 490 |
|
|
2018
Q2 | $9K | Hold |
650
| – | – | 0.01% | 492 |
|
|
2018
Q1 | $12K | Buy |
+650
| New | +$12K | 0.01% | 456 |
|